Article

PODCAST: Dr. Goldfischer on OAB

PODCAST Efficacy and safety study comparing Oxybutynin 3% topical gel vs. placebo in adults with Overactive Bladder Syndrome.



PODCAST: Dr. Goldfischer on OAB

Efficacy and safety study comparing Oxybutynin 3% topical gel vs. placebo in adults with Overactive Bladder Syndrome.







Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Group of surgeons looking at patient on operation table during their work | Image Credit: © Georgii - stock.adobe.com
How residency leave policies affect retention and diversity in surgical specialties
Kevin Shee, MD, outlines factors linked with recurrence after HIFU
Kevin Shee, MD, outlines factors linked with recurrence after HIFU
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Tool predicts prostate cancer outcomes using patient-reported data
Related Content
Ongoing clinical trials and emerging agents in BCG-unresponsive NMIBC
August 25th 2025

Ongoing clinical trials and emerging agents in BCG-unresponsive NMIBC

Hannah Clarke
First Assist: The Historical Context of Advanced Kidney Cancer, with Eric A. Singer, MD
August 25th 2025

First Assist: The Historical Context of Advanced Kidney Cancer, with Eric A. Singer, MD

Taylor Goodstein, MD
Vaginal estrogen tablets not linked with increased risk of recurrent ischemic stroke
August 25th 2025

Vaginal estrogen tablets not linked with increased risk of recurrent ischemic stroke

Hannah Clarke
Introducing First Assist: GU Oncology Unpacked, with Taylor Goodstein, MD!
August 25th 2025

Introducing First Assist: GU Oncology Unpacked, with Taylor Goodstein, MD!

Taylor Goodstein, MD
Novel alpha particle therapy holds promise in prostate, bladder cancer
August 25th 2025

Novel alpha particle therapy holds promise in prostate, bladder cancer

Robert B. Den, MD
Alpha1H shows favorable safety, efficacy in phase 2/3 NMIBC trial
August 25th 2025

Alpha1H shows favorable safety, efficacy in phase 2/3 NMIBC trial

Hannah Clarke
© 2025 MJH Life Sciences

All rights reserved.